Cyclacel Pharma (CYCC) Tops Q2 EPS by 6c

Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.44), $0.06 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Green Dot and CommerceOne shareholders approve acquisition deal
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat